Key terms
About KYMR
Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest KYMR news
Apr 22
9:47am ET
Cisco downgraded, Lucid resumed: Wall Street’s top analyst calls
Apr 22
7:19am ET
Kymera Therapeutics initiated with an Outperform at Oppenheimer
Apr 08
7:09am ET
Kymera Therapeutics announces presentation at AACR annual meeting
Mar 10
11:05pm ET
Promising Future for Kymera Therapeutics: Analyst Endorses ‘Buy’ on Innovative Protein Degradation Compounds
Mar 08
10:07am ET
Kymera Therapeutics presents preclinical data for STAT6, TYK2 degrader programs
Mar 01
9:59am ET
Kymera Therapeutics price target raised to $54 from $41 at Truist
Mar 01
7:35am ET
Kymera Therapeutics (KYMR) Receives a Buy from Truist Financial
Feb 27
7:43am ET
Piper Sandler Keeps Their Buy Rating on Kymera Therapeutics (KYMR)
Feb 27
7:24am ET
Kymera Therapeutics price target raised to $56 from $39 at Piper Sandler
Feb 25
11:27pm ET
Maintaining Hold on Kymera Therapeutics Amidst Promising Pipeline and Industry Challenges
Feb 23
8:42am ET
Kymera Therapeutics price target raised to $45 from $41 at Guggenheim
Feb 23
8:28am ET
Kymera Therapeutics price target raised to $31 from $16 at B. Riley
Feb 23
7:35am ET
Kymera Therapeutics price target raised to $30 from $26 at Wells Fargo
Feb 23
7:32am ET
Stifel Nicolaus Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)
Feb 23
7:17am ET
Kymera Therapeutics price target raised to $55 from $35 at Stifel
Feb 23
6:16am ET
Buy Rating Affirmed for Kymera: Differentiation and Potential of Tyk-2 Program Propel Optimism
Feb 23
6:09am ET
Kymera Therapeutics price target raised to $46 from $30 at H.C. Wainwright
Feb 23
6:01am ET
Maintaining Hold on Kymera Therapeutics with a Cautious Outlook Amidst Pipeline Progression and Financial Stability
Feb 22
3:20pm ET
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR) and Morphic Holding (MORF)
Feb 22
7:05am ET
Kymera Therapeutics sees cash runway into 1H27
Feb 22
7:04am ET
Kymera Therapeutics reports Q4 EPS (25c), consensus (40c)
Feb 14
7:31pm ET
Kymera Therapeutics initiated with a Peer Perform at Wolfe Research
Feb 14
4:17pm ET
Kymera Therapeutics initiated with a Peer Perform at Wolfe Research
No recent press releases are available for KYMR
KYMR Financials
Key terms
Ad Feedback
KYMR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
KYMR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
